6/27/2008

MedImmune chief executive David Mott and the head of research and development, James Young, have resigned, just a year after AstraZeneca PLC's acquisition of the biotech firm. The unexpected departure of Mott, which takes effect at the end of July, and Young, who left his post earlier this month, deals another blow to AstraZeneca and reflects the challenges drugmakers face in keeping prime biotech talent on staff.

Related Summaries